The net buying is notable but dominated by passive rebalancing (State Street, Invesco) rather than conviction-driven active managers. Monitor for a catalyst (pipeline data, regulatory update) before acting on this cluster alone.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-110 4/10
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $247.98entry
- T+1 · 5mo ago +7.50%α +6.96% · $266.58
- T+5 · 5mo ago +8.88%α +8.45% · $270.01
- T+20 · 4mo ago +34.33%α +32.44% · $333.12
- T+60 · 2mo ago +41.87%α +37.47% · $351.81
How similar events traded
Executive Summary
Three institutional investors added $58.3M to PRAX positions in Q3 2025, led by Point72's $39.2M increase, while two sellers trimmed $17.5M. The cluster is mixed, active quant buying (Point72) and passive additions (State Street, Invesco) are partially offset by passive trimming from T. Rowe Price and Morgan Stanley.
Key Financial Metrics
Institutional Positions
Net institutional flow: $40.8M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Point72 | ADD | +56.8% | $79.3M | $39.2M |
| State Street | ADD | +29.9% | $48.1M | $18.7M |
| Invesco | ADD | +30.9% | $1.1M | $436.0K |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | TRIM | -47.5% | $51.6M | -$17.5M |
| T. Rowe Price | TRIM | -31.9% | $62.0K | -$8.8K |
Key Facts
- 3 buyers added $58.3M in aggregate; 2 sellers trimmed $17.5M
- Point72 (quant) increased stake by 56.8% to $79.3M, largest active buyer
- State Street added 29.9% to $48.1M; Invesco added 30.9% to $1.1M
- Morgan Stanley trimmed 47.5% ($17.5M reduction), largest seller
- T. Rowe Price trimmed 31.9% but position value was only $53K
- Cluster dominated by passive/mega-passive funds (4 of 5 funds); only Point72 is active quant
Financial Impact
Net institutional buying of $40.8M (buyers added $58.3M, sellers trimmed $17.5M) in Q3 2025
Risk Factors
- 13F data is 45+ days stale, positions may have been unwound
- Cluster is 80% passive/index funds, active signal is weak
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-PRAX-2025-Q3 |
Track record
16 reports on PRAX
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Viewing Entry $247.98 to $351.81 ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers